iBio Inc.

1.46-0.0400-2.67%Vol 2.46M1Y Perf 55.33%
Apr 9th, 2021 16:00 DELAYED
BID1.44 ASK1.46
Open1.49 Previous Close1.50
Pre-Market- After-Market1.46
 - -  - -%
Target Price
2.78 
Analyst Rating
— 0.00
Potential %
90.41 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★★     56.72
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★★+     63.77
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap315.37M 
Earnings Rating
Buy
Price Range Ratio 52W %
9.52 
Earnings Date
21st May 2021

Today's Price Range

1.451.51

52W Range

0.83007.45

5 Year PE Ratio Range

-5.60-0.7000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-10.43%
1 Month
-12.05%
3 Months
21.67%
6 Months
-28.78%
1 Year
55.33%
3 Years
-30.14%
5 Years
-73.93%
10 Years
-94.77%

TickerPriceChg.Chg.%
IBIO1.46-0.0400-2.67
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
17.70
18.20
0.23
0.31
-8.70
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-919.00
-820.00
-2 007.30
-
RevenueValueIndustryS&P 500US Markets
2.24M
0.01
59.54
23.11
Earnings HistoryEstimateReportedSurprise %
Q02 2021--0.04-
Q01 2021--0.05-
Q03 2020--0.06-
Q02 2020--0.69-
Q01 2020--0.21-
Q03 2019--0.22-
Q01 2019--0.25-
Q03 2018--0.03-
Earnings Per EndEstimateRevision %Trend
6/2021 FY-0.17--
----
----
----
Next Report Date21st May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume2.46M
Shares Outstanding216.01M
Trades Count6.78K
Dollar Volume16.51M
Avg. Volume13.81M
Avg. Weekly Volume2.39M
Avg. Monthly Volume4.21M
Avg. Quarterly Volume13.99M

iBio Inc. (AMEX: IBIO) stock closed at 1.46 per share at the end of the most recent trading day (a -2.67% change compared to the prior day closing price) with a volume of 2.49M shares and market capitalization of 315.37M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 51 people. iBio Inc. CEO is Thomas F. Isett.

The one-year performance of iBio Inc. stock is 55.33%, while year-to-date (YTD) performance is 39.05%. IBIO stock has a five-year performance of -73.93%. Its 52-week range is between 0.83 and 7.45, which gives IBIO stock a 52-week price range ratio of 9.52%

iBio Inc. currently has a PE ratio of -81.50, a price-to-book (PB) ratio of 3.10, a price-to-sale (PS) ratio of 152.71, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -26.09%, a ROC of -25.26% and a ROE of -45.21%. The company’s profit margin is -%, its EBITDA margin is -820.00%, and its revenue ttm is $2.24 Million , which makes it $0.01 revenue per share.

Of the last four earnings reports from iBio Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. iBio Inc.’s next earnings report date is 21st May 2021.

The consensus rating of Wall Street analysts for iBio Inc. is (0), with a target price of $2.78, which is +90.41% compared to the current price. The earnings rating for iBio Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

iBio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

iBio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 26.99, ATR14 : 0.21, CCI20 : -89.37, Chaikin Money Flow : 0.02, MACD : -0.10, Money Flow Index : 31.03, ROC : -20.98, RSI : 43.52, STOCH (14,3) : 38.95, STOCH RSI : 0.84, UO : 46.18, Williams %R : -61.05), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of iBio Inc. in the last 12-months were: James P. Mullaney (Option Excercise at a value of $10 463), James P. Mullaney (Sold 11 250 shares of value $18 113 ), Robert L. Erwin (Option Excercise at a value of $115 685), Robert L. Erwin (Sold 124 392 shares of value $204 059 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Strong Buy
1.00

iBio Inc.

iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: biologics development and licensing activities, conducted within iBio, Inc.

CEO: Thomas F. Isett

Telephone: +1 302 355-0650

Address: 8800 HSC Parkway, Bryan 77807-1107, TX, US

Number of employees: 51

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

33%67%

Bearish Bullish

57%43%

Bearish Bullish

56%44%

Bearish Bullish

63%37%

News

Stocktwits